# Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma

> **NCT07678138** · NA · NOT_YET_RECRUITING · sponsor: **Huanhu Hospital Affiliated to Tianjin Medical University** · enrollment: 9 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Neoantigen DC Vaccine (YS247) for Glioblastoma

## Key facts

- **NCT ID:** NCT07678138
- **Lead sponsor:** Huanhu Hospital Affiliated to Tianjin Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678138, "Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*